<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04230824</url>
  </required_header>
  <id_info>
    <org_study_id>20-PHX-0001 Chronic</org_study_id>
    <nct_id>NCT04230824</nct_id>
  </id_info>
  <brief_title>Chronic Study on Body Composition, Training, Performance, and Recovery</brief_title>
  <official_title>A Randomized, Double-blind, Placebo Controlled, Single-center Study to Determine the Effects of Pre-workout and Recovery Formulations on Soreness, Performance, Tolerance and Safety Outcomes in Healthy Adults Undergoing Training Program</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmanex</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pharmanex</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The chronic phase of the study will evaluate the effects of pre-exercise and post-exercise
      ingestion of a multi-ingredient supplement on adaptations to a 6-week exercise program
      consisting of both resistance training and high intensity aerobic exercise, using a
      randomized, double-blind, placebo-controlled design. Participants will complete an
      enrollment/familiarization visit, a baseline testing session, followed by a 6-week supervised
      exercise intervention, and post-testing session identical to baseline testing. Participants
      will be randomized during the baseline session to groups receiving either 1) Active Treatment
      (pre-post supplementation), 2) placebo (noncaloric beverage), or 3) control, not
      participating in exercise or consuming a treatment. During the supervised 6-week resistance
      training program, participants will complete a moderate-intensity warm-up, a full-body
      resistance training workout (2 x per week) and an interval training session (1 x per week).
      Thirty-minutes prior to each training session, and within 15 minutes post-exercise,
      participants will consume their randomly assigned treatment beverage. Body composition, blood
      markers of muscle damage/recovery, strength, and performance tests will be measured before
      (baseline) and after training (Post) to evaluate the effects of supplementation. All data
      collection will be conducted by the Principal Investigator and Research Assistants. All
      subjects will report to the Applied Physiology Laboratory and Human Performance Center in
      Fetzer Hall for all testing and training sessions, which will span approximately 8 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Strength</measure>
    <time_frame>baseline, week 8</time_frame>
    <description>Change from baseline in strength by measuring 1 repetition maximum for leg press and bench press</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Muscle soreness</measure>
    <time_frame>baseline, week 8</time_frame>
    <description>Change from baseline on muscle soreness using visual analog scale (a horizontal 100 mm line where zero will represent no soreness and one-hundred will represent maximum amount of soreness. Participants will be asked to place a single vertical that represents their current soreness. The scale will be measured with a calibrated ruler with the higher numbers representing more soreness.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recovery</measure>
    <time_frame>baseline, week 8</time_frame>
    <description>Change from baseline on muscle damage by measuring creatine kinase and isoprostanes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Training Volume</measure>
    <time_frame>baseline, week 8</time_frame>
    <description>Change from baseline in total training volume measured by product of sets x repetitions completed x external load used in exercise routine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance</measure>
    <time_frame>baseline, week 8</time_frame>
    <description>Change from baseline on performance by measuring countermovement vertical jump</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Composition</measure>
    <time_frame>baseline, week 8</time_frame>
    <description>Change from baseline in body composition using DXA measurements fat mass (kg) and lean mass (kg)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Damage Muscle</condition>
  <condition>Body Weight Changes</condition>
  <condition>Performance Enhancing Product Use</condition>
  <arm_group>
    <arm_group_label>Pre-workout plus and Protein recovery plus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pre-workout plus: a blend of caffeine, choline bitartrate, carbohydrate, HMB, vitamin D3 mixed with water and consumed within 30 minutes prior to exercise
Protein recovery plus: a blend of whey protein, caseinate, carbohydrate, vitamin C, alpha-tocopherol, vitamin D3, glucosamine mixed with water and consumed 15 minutes post exercise</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Non-caloric powder mixed with water and consumed within 30 minutes prior to exercise and within 15 minutes after exercise</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This arm will receive no intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Pre-workout plus and Protein recovery plus</intervention_name>
    <description>products consumed prior and after exercise</description>
    <arm_group_label>Pre-workout plus and Protein recovery plus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo product consumed prior and after exercise</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>6-week resistance training program</intervention_name>
    <description>participants will complete a moderate-intensity warm-up, a full-body resistance training workout (2 x per week) and an interval training session (1 x per week)</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Pre-workout plus and Protein recovery plus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant is an adult between the ages of 25-50 years

          -  Participant has a recorded BMI of 20-35 kg/m2

          -  Participant exercises less than 3 hours per week for at least 8 weeks preceding the
             study

          -  Participant has provided written and dated informed consent to participate in the
             study

          -  Participant is willing to and able to comply with the protocol

          -  Participant is apparently healthy and no reported metabolic disorders, heart disease,
             arrhythmias, thyroid disease, renal, hepatic, autoimmune or neurological diseases, as
             determined by a health history questionnaire

          -  Participant agrees to maintain current diet and exercise routine during the study

          -  Participant agrees to refrain from taking any anti-inflammatory supplement 48 hours
             prior to exercise or for exercise related pain or medications to prevent any further
             nutritional or drug related protection against exercise induced muscle damage

          -  Participant agrees to wear an accelerometer to track activity during entire study

          -  Participant has a resting (seated for 5 minutes) blood pressure of systolic pressure
             between 140-90 mmHg and a diastolic pressure between 90-50 mmHg

        Exclusion Criteria:

          -  Participant is currently enrolled in a separate clinical trial or weight loss program
             involving diet, exercise, physical activity, or the potential ingestion of an active
             drug or dietary supplement Participant is using, or has consistently used one of the
             following dietary supplements within 12 weeks prior to enrollment: Beta-alanine,
             Creatine, HMB, Carnosine, Vitamin D

          -  Participant has consistently consumed whey protein/plant protein and/or 1,000 mg of
             fish oil within the previous 4 weeks prior to enrollment

          -  Participant has gained or lost â‰¥ 8 lbs in the previous month

          -  Participant has a known allergy or sensitivity to the placebo or active ingredients

          -  Participant has used tobacco more than three days per week (on average) in the
             previous 6 months, or refuses to abstain from all tobacco use for the duration of the
             study

          -  Participant is pregnant or planning to become pregnant

          -  Participant has any musculoskeletal condition prohibiting them from participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abbie Smith-Ryan, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Abbie Smith-Ryan, PhD</last_name>
    <phone>919.962.2574</phone>
    <email>abbiesmith@unc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Abbie Smith-Ryan, PhD</last_name>
      <phone>919-962-2574</phone>
      <email>abbiesmith@unc.edu</email>
    </contact>
    <investigator>
      <last_name>Abbie Smith-Ryan, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 13, 2020</study_first_submitted>
  <study_first_submitted_qc>January 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>January 14, 2020</last_update_submitted>
  <last_update_submitted_qc>January 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Body Weight</mesh_term>
    <mesh_term>Body Weight Changes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

